- Home
- ICG vs CHRS Comparison
ICG vs CHRS Comparison
Compare ICG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICG
- CHRS
- Stock Information
- Founded
- ICG 2017
- CHRS 2010
- Country
- ICG China
- CHRS United States
- Employees
- ICG N/A
- CHRS N/A
- Industry
- ICG Semiconductors
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICG Technology
- CHRS Health Care
- Exchange
- ICG Nasdaq
- CHRS Nasdaq
- Market Cap
- ICG 105.7M
- CHRS 84.2M
- IPO Year
- ICG 2023
- CHRS 2014
- Fundamental
- Price
- ICG $1.97
- CHRS $0.76
- Analyst Decision
- ICG Strong Buy
- CHRS Buy
- Analyst Count
- ICG 2
- CHRS 3
- Target Price
- ICG $9.25
- CHRS $4.68
- AVG Volume (30 Days)
- ICG 155.2K
- CHRS 1.3M
- Earning Date
- ICG 08-14-2025
- CHRS 08-07-2025
- Dividend Yield
- ICG N/A
- CHRS N/A
- EPS Growth
- ICG N/A
- CHRS N/A
- EPS
- ICG 0.07
- CHRS N/A
- Revenue
- ICG $53,729,346.00
- CHRS $272,251,000.00
- Revenue This Year
- ICG N/A
- CHRS N/A
- Revenue Next Year
- ICG $141.94
- CHRS $106.56
- P/E Ratio
- ICG $24.17
- CHRS N/A
- Revenue Growth
- ICG 384.54
- CHRS 19.87
- 52 Week Low
- ICG $1.19
- CHRS $0.66
- 52 Week High
- ICG $12.04
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- ICG 52.28
- CHRS 46.35
- Support Level
- ICG $1.57
- CHRS $0.72
- Resistance Level
- ICG $1.95
- CHRS $0.77
- Average True Range (ATR)
- ICG 0.26
- CHRS 0.04
- MACD
- ICG 0.03
- CHRS 0.00
- Stochastic Oscillator
- ICG 88.47
- CHRS 38.69
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.